Rani Therapeutics to Present at the Jefferies Healthcare Conference
June 01, 2023 08:00 ET
|
Rani Therapeutics, LLC
SAN JOSE, Calif., June 01, 2023 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral...
Rani Therapeutics Announces Acceptance of Three Abstracts for Presentation at ENDO 2023 Annual Conference
May 31, 2023 08:00 ET
|
Rani Therapeutics, LLC
SAN JOSE, Calif., May 31, 2023 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral...
Rani Therapeutics Appoints Kate McKinley as Chief Business Officer
May 24, 2023 08:00 ET
|
Rani Therapeutics, LLC
SAN JOSE, Calif., May 24, 2023 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral...
Rani Therapeutics Reports First Quarter 2023 Financial Results; Provides Corporate Update
May 10, 2023 16:05 ET
|
Rani Therapeutics, LLC
- Announced partnership with Celltrion on development of RT-111, a RaniPill GO capsule containing a biosimilar for the monoclonal antibody ustekinumab - - Received preliminary feedback from FDA on...
Rani Therapeutics to Participate in the H.C. Wainwright BioConnect Investor Conference at NASDAQ
April 25, 2023 08:00 ET
|
Rani Therapeutics, LLC
SAN JOSE, Calif., April 25, 2023 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral...
Rani Therapeutics to Present at the 22nd Annual Needham Virtual Healthcare Conference
April 11, 2023 08:00 ET
|
Rani Therapeutics, LLC
SAN JOSE, Calif., April 11, 2023 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral...
Rani Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results; Provides Corporate Update
March 22, 2023 16:05 ET
|
Rani Therapeutics, LLC
- Anticipates initiating first Phase 2 clinical study in RT-102 in 2H of 2023 - - Announced topline results from the Phase 1 repeat-dose study of RT-102 for the treatment of osteoporosis - -...
Rani Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results and Business Updates
March 16, 2023 16:05 ET
|
Rani Therapeutics, LLC
SAN JOSE, Calif., March 16, 2023 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral...
Celltrion and Rani Therapeutics Partner on Development of Oral Monoclonal Antibody Treatment
January 09, 2023 08:30 ET
|
Rani Therapeutics, LLC
SAN JOSE, Calif., Jan. 09, 2023 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral...
Rani Therapeutics Receives Feedback from Pre-IND Meeting with FDA; Provides Pipeline Update
January 05, 2023 16:05 ET
|
Rani Therapeutics, LLC
- Preliminary feedback from FDA on RT-102 development plans; 505(b)(2) pathway for RT-102 could be suitable - - Multiple anticipated clinical milestones expected in 2023, including initiation of...